期刊文献+

核转染技术转染人外周血淋巴细胞效率的初步研究 被引量:1

Preliminary Study on Electroporation of Human Peripheral Blood Lymphocyte
在线阅读 下载PDF
导出
摘要 目的探索核转染技术转染人外周血淋巴细胞的转染效率。方法利用核转染方法将携带增强型绿色荧光蛋白基因的质粒转染人外周血淋巴细胞,24小时后经流式细胞仪检测绿色荧光蛋白EGFP表达水平,确定转染效率。结果未经任何刺激的外周血淋巴细胞转染效率为8.7%,经抗CD3抗体OKT3和抗CD28抗体共同刺激后的外周血淋巴细胞转染效率为10.5%,经抗CD3抗体OKT3和IL-2共同刺激后的外周血淋巴细胞转染效率为9.9%。结论核转染方法是一种转染人外周血淋巴细胞的有效方法,转染前细胞是否受到刺激激活,对转染的效率影响不大。 Objective To determine the transfection efficiency of human peripheral blood lymphocyte with electroporation.Method The plasmid which contained EGFP gene were transfected by nucleofector transfection method,then the expression of EGFP were calculated by flow cytometry after 24 hours.Results The transfection efficiency of unstimulated lymphocytes is 8.7%.It is 10.5% for the T cells stimulated by anti-CD3/anti-CD28 antibodies and 9.9% for the T cells stimulated by anti-CD3/IL-2.Conclusion The nucleofector-based electroporation is an efficient method to transfect peripheral blood lymphocytes.The activation of T cells has no influence on transfection efficiency.
出处 《肿瘤药学》 CAS 2012年第1期28-30,共3页 Anti-Tumor Pharmacy
关键词 外周血淋巴细胞 核转染 转染效率 Peripheral blood lymphocyte Nucleofection Transfection efficiency
  • 相关文献

参考文献15

  • 1Ioannides CG,Freedman RS,Platsoucas CD. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells[J].Journal of Immunology,1991,(05):1700-1707.
  • 2王建军,王泽友.miRNA与肿瘤的研究进展[J].肿瘤药学,2011,1(3):169-172. 被引量:3
  • 3Dunbar PR,Chen JL,Chao D. Cutting edge:rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma[J].Journal of Immunology,1999,(12):6959-6962.
  • 4Dudley ME,Wunderlich JR,Robbins PF. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes[J].Science,2002,(5594):850-854.
  • 5Vignard V,Lemercier B,Lim A. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells[J].Journal of Immunology,2005,(07):4797-4805.
  • 6Hans J Stauss,Michela Cesco-Gaspere,Sharyn Thomas. Monoclonal T-cell receptors:New reagents for cancer therapy[J].Molecular Terapy,2007.1744-1750.
  • 7Carl H.June,Bruce R.Blazar,James L Riley. Engineering lymphocyte subsets:tools,trials and tribulations[J].Nat Reviews Immunology,2009.704-716.
  • 8Voss R.H,J Kuball,M Theobald. Designing TCR for cancer immunotherapy[J].Methods in Molecular Medicine,2005.229-256.
  • 9孙燕.肿瘤治疗的新里程碑——靶向药物治疗[J].肿瘤药学,2011,1(1):1-5. 被引量:47
  • 10Clay TM,Custer MC,Spiess PJ. Potential Use of T Cell Receptor Genes to Modify Hematopoietic Stem Cells for the Gene Therapy of Cancer[J].Pathology Oncology Research,1999,(01):3-15.

二级参考文献36

  • 1孙燕.肿瘤药物治疗百年回顾与展望[J].中华肿瘤杂志,2004,26(11):701-703. 被引量:16
  • 2周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 3王燕,张湘茹,朱红霞,王彬,徐宁志,孙燕.吉非替尼治疗非小细胞肺癌的临床疗效预测模型的初步建立[J].中华医学杂志,2007,87(43):3069-3073. 被引量:15
  • 4Maki Ando,Yoshinori Hasegawa,Yuichi Ando.Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan[J]. Investigational New Drugs . 2005 (6)
  • 5Kremer JM.Methotrexate pharmacogenomios. Annals of the Rheumatic Diseases . 2006
  • 6Gurubhagavatula S,Liu G,Park S,et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Journal of Clinical Oncology . 2004
  • 7EvansWE.PharmacogeneticsofthiopurineS methyltrans feraseandthiopurinetherapy. Therapeutic Drug Monitoring . 2004
  • 8Stanulla M,Schaeffeler E,Flohr T et al.Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. The Journal of The American Medical Association . 2005
  • 9Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, The . 2004
  • 10Mitsudomi T,Kosaka T,Endoh H,Horio Y,Hida T,Mori S,Hatooka S,Shinoda M,Takahashi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology . 2005

共引文献75

同被引文献4

引证文献1

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部